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Background: The emergence and spread of extended-spectrum β-lactamases (ESBLs), espe-
cially CTX-M, is an important public health problem with serious implications for low-income 
countries where second-line treatment is often unavailable. Knowledge of the local prevalence 
of ESBL is critical to define appropriate empirical therapeutic strategies for multidrug-resistant 
(MDR) organisms. This study aimed to assess and characterize the presence of ESBL and 
especially CTX-M-producing Escherichia coli MDR isolates from patients with urinary tract 
infections (UTIs) and bacteremia in a rural hospital in Mozambique.
Materials and methods: One hundred and fifty-one E. coli isolates from bacteremia and 
UTI in children were screened for CTX-M, TEM, SHV and OXA β-lactamases by polymerase 
chain reaction and sequencing. Isolates carrying CTX-M group 1 β-lactamases were further 
studied. The resistance to other antibiotic families was determined by phenotypic and genotypic 
methods, the location of the bla
CTX-M
 gene and the epidemiology of the isolates were studied, 
and extensive plasmid characterization was performed.
Results: Approximately 11% (17/151) of E. coli isolates causing bacteremia and UTI were 
ESBL producers. CTX-M-15 was the most frequently detected ESBL, accounting for 75% of 
the total isolates characterized. The bla
CTX-M 
gene is located in different plasmids belonging to 
different incompatibility groups and can be found in non-epidemiologically related isolates, 
indicating the high capacity of this resistance determinant to spread widely. 
Conclusion: Our data suggest the presence of a co-selection of third-generation cephalosporin-
resistant determinants in the study area despite limited access to these antibiotics. This high-
lights the importance of continuous surveillance of antimicrobial resistance of both genetic 
elements of resistance and resistant isolates in order to monitor the emergence and trends of 
ESBL-producing isolates to promote adequate therapeutic strategies for the management of 
MDR bacterial infections.
Keywords: CTX-M-15, multidrug-resistance, Enterobacteriaceae, resistance determinant 
location
Introduction
Infections caused by members of the Enterobacteriaceae family are among the major 
causes of hospital admission and associated morbidity and mortality in children, 
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particularly in Africa.1,2 Infections caused by these microor-
ganisms in low- and middle-income countries (LMIC) have 
been successfully treated with the inexpensive antibiotics 
available. Nevertheless, with the widespread development 
of multidrug-resistant (MDR) strains, the usefulness of the 
early effective antibiotics has greatly decreased,3,4 leading 
to the introduction of broad-spectrum antibiotics such as 
fluoroquinolones or third-generation cephalosporins (cefo-
taxime, ceftriaxone, or ceftazidime). Unfortunately, these 
agents are often unaffordable in most LMIC, especially in 
remote rural areas.
On the other hand, since their first description in 1983, 
extended-spectrum β-lactamases (ESBLs) produced by 
enteric pathogens have spread worldwide.5
The emergence and spread of ESBLs, especially those 
included in the CTX-M group, is an important public health 
problem.6 In fact, it has been considered that ESBL-carrying 
Enterobacteriaceae cause >1700 deaths yearly in the USA 
alone,7 and these pathogens have had a tremendous impact 
on the treatment of severe or MDR-associated infections, 
particularly in LMIC where second-line antibiotics are often 
unaffordable or unavailable. In addition, few new antibiotics 
against Gram-negative bacteria have been marketed in the last 
decades8 which may favor the emergence of new resistances, 
further challenging the management of infectious diseases in 
this setting. This may play a role in the high morbidity and 
mortality observed in these countries, particularly in children 
<5 years of age.
Although different types of ESBLs have been reported 
among the Enterobacteriaceae family, CTX-M-15, a commu-
nity-acquired ESBL that was originally described in India 
in the 1990s, is one of the most frequent type I CTX-M dis-
seminated worldwide.9 The genes encoding ESBL enzymes 
are usually located in plasmids but can also be found in the 
chromosomal DNA as described elsewhere.10 It has been 
reported that the bla
CTX-M-15 
gene is usually found downstream 
from the insertion sequence ISEcp1 that may be involved 
in their dissemination and expression.11 Plasmid-mediated 
ESBL genes are of special interest due to their capability of 
getting transferred between strains or even species, favor-
ing their dissemination among the bacterial population and 
from region to region. Moreover, these plasmids usually 
carry other antibiotic resistance determinants, resulting not 
only in the spread of ESBL but also in the dissemination 
of other resistance genes.12 The selection of one resistance 
gene due to environmental pressure harbored in the same 
genetic element as another resistance gene or genes is known 
as the co-selection of resistance genes phenomenon. Since 
ESBL-producing microorganisms are also often resistant 
to other commonly available antibiotics, including fluoro-
quinolones, especially in most LMIC,13 knowledge of their 
prevalence and characterization is important for defining 
local empirical stewardship programs for infections caused 
by MDR organisms.
In Africa, ESBLs have increasingly been reported.14,15 In 
Mozambique, the prevalence of these pathogens is extremely 
high, although the data available are limited to only a few 
studies.16 Herein, we report the prevalence of Escherichia 
coli harboring the ESBL gene bla
CTX-M 
group I as well as its 
molecular characterization and epidemiology among isolates 
recovered from blood cultures and urine in a rural hospital 
in Southern Mozambique.
Materials and methods
Study population and clinical isolates
The study was conducted by the Centro de Investigação em 
Saúde de Manhiça (CISM) at the Manhiça District Hospital, 
a rural referral hospital of the Manhiça district, located 80 km 
north of Maputo, in Southern Mozambique. Invasive bacterial 
disease surveillance has been conducted in the pediatric popu-
lation in this area since 1997. The full description and charac-
teristics of the study area are detailed elsewhere.17 As described 
previously in standard clinical protocols, blood cultures are 
systematically collected upon admission of all children up to 
14 years of age with an axillary temperature ≥37.5°C or meet-
ing criteria of severe infection.2 We analyzed E. coli isolates 
recovered from children with community-acquired bacteremia 
between August 2004 and December 2009. Urine samples 
were also collected during the same study period from patients 
(adults and children) visited at the outpatient department or 
admitted to the hospital with clinical suspicion of urinary tract 
infection (UTI). All the isolates included in the present study 
were recovered from different patients.
Bacterial culture and identification
Blood culture tubes were incubated in an automated system 
(BACTEC® 9050; Becton Dickinson, Franklin Lakes, NJ, 
USA). Positive blood cultures were subcultured in solid 
media after Gram staining as appropriate. Urine samples 
were microscopically screened after centrifugation, and those 
with pathologic sediment (presence of leucocytes or bacteria) 
were cultured in MacConkey and blood agar media. Patho-
gens were identified according to conventional microbiology 
protocols. Among the Enterobacteriaceae isolates identified, 
ceftriaxone susceptibility was tested by disk diffusion in 
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Characterization of multidrug-resistant E. coli harboring blaCTX-M group 1
according to the Clinical and Laboratory Standard Institute 
(CLSI) 2013 guidelines.18 The selected ceftriaxone non-sus-
ceptible E. coli isolates were screened for the ESBL enzyme 
CTX-M group 1 and the positive isolates were included in 
the study. The isolates were confirmed by matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) prior to further analysis.19
Antimicrobial susceptibility testing
The susceptibility phenotype for ampicillin, chlorampheni-
col, ceftriaxone, gentamicin, tetracycline, trimethoprim-
sulfamethoxazole, rifampicin, and amikacin was determined 
by a conventional disk diffusion method and for nalidixic 
acid and ciprofloxacin by minimum inhibitory concentration 
(MIC). The interpretative category of resistance for disk 
diffusion and MIC were done according to the CLSI 2013 
guidelines.18 Antimicrobial susceptibility testing of the iso-
lates was also performed by Siemens MicroScan panels NEG 
MIC TYPE 37. The E. coli American Type Culture Collec-
tion 25922 strain was used as the quality control. Multidrug 
resistance was defined as resistance to 3 or more unrelated 
antibiotic families.20 Resistance genes to quinolones and 
rifampicin were also studied by polymerase chain reaction 
(PCR) and sequencing methods using primers for aac (6’)-Ib-
cr, qnrA, qnrB, qnrC, qnrD, qnrS, qepA, gyrA, parC, arr2,3, 
arr4, arr5, arr6, arr7, arr3, and rpoB already described.21–29
ESBL phenotype detection
All ceftriaxone non-susceptible E. coli isolates were phe-
notypically screened for the presence of ESBL. Phenotypic 
confirmation of ESBL expression was carried out using the 
ESBL disk synergy test with disks containing cefotaxime, 
amoxicillin with clavulanate, and ceftazidime on Muel-
ler–Hinton agar (Oxoid) as described elsewhere.30 E. coli 
isolates with an ESBL phenotype were tested by PCR for the 
presence of genes encoding β-lactamases and were further 
characterized as follows.
β-lactamases analysis
The presence of bla
CTX-M 
was detected by PCR using universal 
primers, while the bla
CTX-M 
groups 1, 2, 8, 9, and bla
CTX-M-15 
were determined using specific CTX-M group primers 












was also determined by PCR and sequencing as described 
elsewhere.32 The presence of the insertion sequence ISEcp1 
upstream from the bla
CTX-M 
genes was determined by PCR 
and sequencing as previously described.11 Sequencing of the 
genes was performed by the Macrogen® DNA Sequencing 
Service (Macrogen, Amsterdam, the Netherlands) using sets 
of consecutive primers specific for each gene type.
Class I integron analysis
The presence of class I integrons was analyzed in all the E. 
coli isolates. A PCR was carried out with primers 3′CS and 
5′CS as described by Lévesque et al33 and the amplicons 
obtained were sequenced by Beckman Coulter Sequencing 
Genomics® sequencing facilities (Takeley, UK).
Typing
Pulsed-field gel electrophoresis (PFGE) was performed with 
the XbaI restriction enzyme (New England Biolabs, Beverly, 
MA, USA) as described previously.34 PFGE profiles were 
analyzed with InfoQuest FP software version 4.5 (Bio-Rad 
Laboratories Inc., Hercules, CA, USA). In order to establish 
the epidemiological relationship among the isolates from the 
electrophoretic patterns, the Dice coefficient was used and 
clustering was based on the unweighted pair group method 
with arithmetic mean with a 1% tolerance in band position 
differences. The isolates were considered to belong to the same 
epidemiological group when the PFGE-XbaI profiles showed 
≥80% of homology, adapting the criteria described by Tenover 
et al.35 Multi-locus sequence typing (MLST) was carried out 
by amplification and sequencing of the 7 E. coli housekeeping 
genes as described previously.36 The database available at http://
mlst.warwick.ac.uk/mlst/dbs/Ecoli/ was used for assigning 
sequence types (STs) and clonal complexes (CCs). Classifi-
cation of isolates into E. coli phylogenetic groups was done 
using a previously described triplex PCR-based protocol.37
Plasmid transferability analysis
Conjugation assays were carried out with all the isolates in 
order to determine if the bla
CTX-M 
group 1 gene was located in 
a conjugative plasmid adapting the protocol described else-
where.38 The E. coli K7 759 lac- kanamycin-resistant isolate 
was used as the recipient strain. Both parental and recipient 
strains were cultured over-night (ON) with Luria Bertani 
(LB) broth (Laboratorios Conda, Barcelona, Spain). The 
parental isolates were grown in LB medium supplemented 
with 32 µg/mL of cefotaxime in order to force resistance 
determinant replication. An aliquot of 500 µL of a parental 
isolate subcultured for 2 hours was mixed with the same 
volume of the recipient strain and cultured ON at 37°C. 
Transconjugant strains were finally grown in MacConkey 
agar plates supplemented with 256 µg/mL of kanamycin and 
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PCRs and a bla
CTX-M 
group 1 PCR were performed to ensure 
the correct selection of the transconjugants.39
The blaCTX-M gene location
Considering the previously described large size of the plas-
mids carrying bla
CTX-M 
group 1 ESBL genes,40 a S1 nuclease 
(Promega, Madison, WI, USA) digestion followed by PFGE 
analysis were performed in the 12 E. coli isolates and the 
transconjugants obtained as described elsewhere.41 To deter-
mine the plasmid or chromosomal location of the ESBL-
encoding gene, a Southern blot of the PFGE gel followed by 
hybridization with a bla
CTX-M 
group 1 probe was carried out.
PCR-based Replicon Typing (PBRT)
Plasmids from both parental and transconjugant isolates were 
assigned to incompatibility groups depending on the presence 
of specific replicon sequences identified by PCR using the 
primers designed by Carattoli et al in 2005 but employing the 
adapted amplification protocols for commensal and patho-
genic E. coli isolates described by Johnson et al.42
Ethical clearance
The strains characterized here were isolated from the ongoing 
invasive bacterial surveillance system that included several 
research protocols reviewed and approved by the Mozambi-
can National Bioethics Committee for Health (IR00002657) 
and by Institutional Review Boards of Hospital Clinic of 
Barcelona, Spain; the US Centers for Disease Control and 
Prevention; and the School of Medicine, University of Mary-
land. Written informed consent was obtained from parents 
or caretakers of the eligible children.
Results
Study population and clinical isolates
During the study period, a total of 15,057 blood cultures 
were collected and 1325 (8.8%) were found to be positive for 
any pathogen evaluable. Of these, 27.7% were identified as 
belonging to the Enterobacteriaceae family, with E. coli being 
the second most frequent after non-typhoidal Salmonella, 
accounting for 29% (106/368). Among these, 8 out of 12 E. 
coli isolates non-susceptible to ceftriaxone and positive for 
the ESBL disk synergy test (11.3% of total E. coli isolates) 
were found to carry a bla
CTX-M
 group I gene.
Of the 298 urine samples cultured for bacterial isolation, 
35% (n=103) were positive for pathogenic bacteria. Among 
these, 81 (78.6%) corresponded to Enterobacteriaceae with 
E. coli being the most prevalent species with 45 isolates of 
which 5 (11.1%) were non-susceptible to ceftriaxone and 
positive for the ESBL double-disk synergy test. Four were 
found to carry a bla
CTX-M
 group I gene.
A total of 12 E. coli isolates from bacteremia and UTI 
carrying a bla
CTX-M
 group I gene were selected for further 
characterization.
β-lactamases analysis
Gene amplification sequencing revealed that 92% (n=11) of 
the isolates harbored bla
CTX-M-15
, while the remaining strain 
presented the ESBL gene bla
CTX-M-37
. The non-ESBL resis-




, were found 
in 100% and 58.3% of the isolates, respectively. Another 
ESBL-encoding gene detected was bla
SHV-12
, which was 
found in 2 of the isolates also presenting bla
CTX-M-15
. In all 
cases, the insertion sequence ISEcp1 was found upstream 
from the bla
CTX-M 
group 1 gene. The overall results are sum-
marized in Table 1.
Antimicrobial susceptibility testing
All the isolates were MDR, presenting not only resistance 
to third-generation β-lactams (ceftriaxone) but also to 
other classes of antimicrobial agents. All the isolates were 
resistant to rifampicin, gentamicin, chloramphenicol, and 
trimethoprim-sulfamethoxazole, while 66.7% were resistant 
to quinolones (Table 1). Regarding the resistance genotype of 
the E. coli isolates to quinolones, among the isolates with a 
MIC=1 µg/mL of ciprofloxacin, 4 showed the presence of the 
qnrB gene without mutations in the gyrA and parC genes; 1 
isolate showed only a mutation in amino acid codon Ser83 of 
gyrA and 1 did not show any of the resistance determinants 
studied. The isolate with a MIC=64 µg/mL of ciprofloxacin 
showed 3 mutations (2 in gyrA and 1 in parC) and the other 
isolate with a MIC >256 µg/mL has the same mutations plus 
the presence of the qnrB gene (Table 2).
The resistance genotype to rifampicin was not well elu-
cidated as arr genes were not detected and any significant 
mutations in rpoB gene were observed in any isolate.
All the isolates were susceptible to fosfomycin, nitrofu-
rantoin, and carbapenems.
Class 1 integron analysis
Seven isolates were found to carry class 1 integrons. Two isolates 
harbored an integron of ~1000 bp carrying the resistance 
gene aadA1, conferring resistance to streptomycin and 
spectinomycin. One isolate had a 2000 bp class 1 integron 
carrying 2 resistance genes: dfrA12 and aadA2 that confer 
resistance to trimethoprim and streptomycin-spectinomycin, 
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Characterization of multidrug-resistant E. coli harboring blaCTX-M group 1
Table 1 Study strains, β-lactamase analysis, resistance profile and class I integron characterization
Isolate Source Isolation 
date







in Integron class I
E12 Blood 09/10/2008 CTX-M-15 TEM-1 CHL-GM-TET-SXT-RIF − −
E15 Blood 15/04/2009 CTX-M-15 TEM-1 CHL-GM-TET-SXT-RIF − −
E11 Blood 15/09/2008 CTX-M-15 TEM-1/OXA-1 CHL-GM-CIP-TET-SXT-RIF 1000 bp aadA1
E4 Blood 04/05/2007 CTX-M-15/SHV-12 TEM-1 CHL-GM-NAL-TET-SXT-RIF − −
E3 Blood 14/12/2006 CTX-M-15 TEM-1 CHL-GM-TET-SXT-RIF − −
E16 Blood 29/03/2009 CTX-M-15 TEM-1/OXA-1 CHL-GM-NAL-CIP-TET-SXT-RIF 1000 bp aadA1
E18 Blood 10/11/2008 CTX-M-15 TEM-1 CHL-GM-SXT-RIF 2000 bp dfrA12 + aadA2
E2 Urine 23/11/2005 CTX-M-15 TEM-1/OXA-1 CHL-GM-NAL-CIP-TET-SXT-RIF − −
E7 Blood 26/12/2007 CTX-M-15 TEM-1/OXA-1 CHL-GM-NAL-CIP-TET-SXT-RIF 800 bp/1000 bp dfrA16/aadA1
E14 Urine 13/02/2009 CTX-M-15 TEM-1/OXA-1 CHL-GM-NAL-CIP-TET-SXT-RIF 800 bp/1000 bp dfrA16/aadA1
E8 Urine 30/07/2008 CTX-M-37 TEM-1/OXA-1 CHL-GM-NAL-CIP-TET-SXT-RIF 800 bp/1000 bp dfrA16/aadA1
E17 Urine 20/03/2009 CTX-M-15/SHV-12 TEM-1/OXA-1 CHL-GM-NAL-CIP-TET-SXT-RIF 800 bp/1000 bp dfrA16/aadA1
Abbreviations: CHL, chloramphenicol; CIP, ciprofloxacin; ESBL, extended-spectrum β-lactamases; GM, gentamicin; NAL, nalidixic acid; RIF, rifampicin; SXT, trimethoprim-
sulfamethoxazole; TET, tetracycline.
Table 2 Quinolone susceptibility phenotype and genotype
Isolate Minimum inhibitory 
concentration (µg/mL)
Resistance genes Aminoacidic mutations
NAL CIP qnrA qnrB qnrC qnrD qnrS qepA aac (6’) Ib-cr gyrA parC
83 (wt Ser) 87 (wt Asp) 80 (wt Ser) 84 (wt Glu)
E2 >256 R 64 R − − − − − − − Leu Asn Ile Glu
E3 4 S 0.03 S − − − − − − − − − − −
E4 128 R 1 I − − − − − − − Leu Asp Ser Glu
E7 16 I 1 I − + − − − − − Ser Asp Ser Glu
E8 16 I 1 I − − − − − − − Ser Asp Ser Glu
E11 >256 R >256 R − + − − − − − Leu Asn Ile Glu
E12 1 S 0.007 S − − − − − − − − − − −
E14 16 I 1 I − + − − − − − Ser Asp Ser Glu
E15 4 S 0.015 S − − − − − − − − − − −
E16 16 I 1 I − + − − − − − Ser Asp Ser Glu
E17 16 I 1 I − + − − − − − Ser Asp Ser Glu
E18 8 S 0.5 S − − − - − − − − − − −
Abbreviations: CIP, ciprofloxacin; NAL, nalidixic acid; R, resistant; I, intermediate; S, susceptible; Leu, leucine; Ser, serine; Asn, asparagine; Asp, aspartic acid; Ile, isoleucine; 
Glu, glutamic acid.
1000 bp  containing the dfrA16 and aadA1 genes, respectively, 
conferring the same resistances as those mentioned earlier 
(Table 1).
Molecular typing
According to the PFGE analysis constructed from the elec-
trophoresis patterns of the XbaI restriction and considering 
the same profile of ≥80% of similarity, there were 8 differ-
ent epidemiological groups among the 12 isolates studied. 
The analysis showed 4 and 2 other isolates to be in the same 
epidemiological group, thereby being epidemiologically 
related isolates. This association, however, involved group-
ing isolates harboring different bla
CTX-M
 group 1 genes. 
The MLST analysis also showed the same number of ST 
groups as epidemiologically unrelated isolates (singletons). 
This data correlates 100% with the epidemiological group-
ing established by the PFGE analysis and with the genetic 
characterization of non-β-lactam resistance genes and the 
antimicrobial susceptibility profiles. Only 2 out of the 8 STs 
described belonged to the same CC (ST10). Four E. coli 
phylogenetic groups were represented in the collection of 
isolates (A, B1, B2, and D), with none having a statistically 
significant prevalence taking into account the epidemiologi-
cal associations. All the isolates causing UTI belonged to 
phylogenetic group A (Table 3).
Plasmid characterization
Transconjugants were obtained from 10 parental isolates as 
shown in Table 4. S1 endonuclease digestion allowed visual-
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Table 3 Typing and epidemiological relationship between the Escherichia coli isolates
Isolate Phylogenetic 
group
Sequence type Clonal complex PFGE profile Dendrogram
E12 B1 ST3 ST3
E15 B1 ST3 ST3   
E11 D ST405 ST405   
E4 D ST38 ST38   
E3 B2 ST2451 Singleton   
E16 A ST10 ST10   
E18 B1 ST453 ST86   
E2 A ST617 ST10   
E7 A ST216 Singleton   
E14 A ST216 Singleton   
E8 A ST216 Singleton   
E17 A ST216 Singleton   
80% similarity
Abbreviations: PFGE, pulsed-field gel electrophoresis; ST, sequence type.
Table 4 Plasmid transferability assay and characterization
Donor isolates Transconjugants








E12 3 FIIA E12T FIIA
E15 3 FIIA E15T FIIA
E11 3 HI2/FIB E11T HI2
E4 2 HI2 Not obtained −
E3 3 FIB E3T None
E16 1 HI2 E16T HI2
E18 1 FIB E18T None
E2 1 FIA Not obtained −
E7 2 HI2 E7T HI2
E14 2 HI2 E14T HI2
E8 2 HI2 E8T None
E17 2 HI2 E17T HI2
The plasmid incompatibility groups amplified in the 
PBRT analysis of the parental isolates were IncFIIA, IncFIA, 
IncHI2, and IncFIB, but only the incompatibility groups 
IncFIIA and IncHI2 were found in the plasmids carrying 
the bla
CTX-M 
group 1 gene (such as those amplified in the 
transconjugants; Table 4).
Discussion
This is one of the few studies on the prevalence of CTX-M 
group 1 ESBLs in E. coli causing both bacteremia and 
UTIs among children in Mozambique. The prevalence 
of ESBLs reported here is a matter of concern as MDR 
pathogens causing infectious diseases are common in this 
area, limiting the therapeutic options for treating severe 
infections often associated with a poor outcome. The rates 
of ESBLs and other antibiotic resistances observed in this 
study may be associated with the high prevalences of other 
infectious diseases, such as tuberculosis, respiratory infec-
tions, malaria, and human immunodeficiency virus, which 
requires the frequent use of antibacterial agents.43–45 Despite 
the high prevalence of ESBLs reported in this study, it is 
lower compared with the prevalence of those causing UTIs 
in children admitted to the malnutrition and pediatric wards 
described in the central region of the country (Beira City).46
Regarding the resistance mechanisms to non-β-lactamic 
antibiotic families found among the E. coli isolates studied, 
the resistance determinants to quinolones correspond to those 
described so far,47 whereas the lack of detection of resistance 
determinants to rifampicin suggests other mechanisms of 
resistance, such as the effect of efflux pumps, as described 
elsewhere.29
carried 1, 2, or even 3 plasmids each, ranging from <48.5 kb 
to ~380 kb (Figure 1). Hybridization with the bla
CTX-M 
group 
1 probe allowed the localization of the plasmid carrying the 
antimicrobial resistance determinant in each isolate, which 
appeared to be of 3 different plasmid sizes among the 8 epi-
demiological groups (Figure 2). However, epidemiologically 
related isolates carried plasmids with different sizes harbor-
ing the resistance determinant. The conjugative plasmid in 
isolate E8 carrying bla
CTX-M-37
 was the smallest (<48.5 Kb), 
whereas in the epidemiologically related isolates carrying 
bla
CTX-M-15
, the conjugative plasmid was the largest (~290 
Kb). The transconjugant E11T showed a hybridization signal 
in a larger-sized plasmid from its donor isolate. Isolates in 
which conjugation was not possible (E2 and E4) only showed 
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Figure 1 S1 endonuclease pulsed-field gel electrophoresis (PFGE).
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The most prevalent resistance mechanism to third-
generation cephalosporins found in the collection of MDR 
isolates studied is the bla
CTX-M 
gene belonging to a sublineage 
or group I (accounting for 70.6% of the ESBL-carrying 
isolates), which is consistent with other reports5 showing 
isolates harboring a bla
CTX-M 
group I gene with almost 92% 
being bla
CTX-M-15
. Within the CTX-M-1 group, bla
CTX-M-15 
is 
the most frequently described resistance gene in isolates 
causing both community-acquired bacteremia and UTI.6,16 
In fact, bla
CTX-M-15 
is currently the most common variant 
detected worldwide in clinically important Gram-negative 
bacteria together with bla
CTX-M-14
.9 According to the current 
data and the widely reported bla
CTX-M-15 
dissemination, this 
is not the first description of this gene in the area since it 
has previously been described in ESBL-carrying Klebsiella 
pneumoniae isolates.16
Regarding the other bla
CTX-M 
group I gene detected, this 
is the first description of bla
CTX-M-37 
in Mozambique. This 
infrequently detected CTX-M was first described in an 
Enterobacter cloacae isolated in Mongolia in 2002, and 
to our knowledge, it has only been previously reported 
in 1 other African country, the neighboring South Africa, 
as well as in the chromosome of an isolate of Kluivera 
cryocrescences from Argentina (GenBank access No: 
FN813246.1).48
Whereas the mechanism of resistance to third-generation 
cephalosporins in the collection of isolates of our study 
was the same, the isolates showed low relatedness at an 
epidemiological level, being distributed in 4 phylogenetic 
groups and 8 epidemiological groups. Although the range of 
phylogenetic groups represented is wide, it is important to 
highlight that all the isolates from UTIs were phylogenetic 
group A. This phylogenetic group has been associated with 
MDR strains causing UTI.49 Based on PFGE and MLST 
results, 4 isolates within the same epidemiological group 
belonged to ST ST216. However, these isolates showed 
some divergent evolution concerning the resistant determi-
nants, as one harbored CTX-M-37 (isolate E8) instead of 
CTX-M-15 and another (isolate E17) also showed SHV-12. 
Furthermore, isolates E12 and E15 belonged to the same 
epidemiological group although they were isolated at a 
different period. The non-related isolates belonged to dif-
ferent STs and even different CCs, indicating that it was 
not a clonal dissemination.
Regarding the plasmid analysis to determine the location 
of bla
CTX-M 
group 1, the collection presented a wide range of 
different plasmid incompatibility groups. Furthermore, 2 
epidemiologically unrelated isolates harbored the resistance 
determinant in the chromosome and, therefore, no trans-
conjugants were obtained. The transconjugant E11 showed 
a hybridization signal in a larger plasmid from its donor 
isolate, but its size corresponded to the recombination of 
the 2 plasmids harbored by the parental isolate, a common 
phenomenon in conjugation assays. Moreover, together with 
E16, which belongs to ST ST10, this isolate harbored the 
same plasmid (in terms of size and incompatibility group) 
as the isolates belonging to the clone ST216, suggesting a 
potential dissemination of the same plasmid among E. coli 
strains belonging to different STs.
The location of the bla
CTX-M 
gene upstream from the 
insertion sequence ISEcp1 in all the isolates and in a 
conjugative plasmid in most of the isolates implies a high 
potential of dissemination of this ESBL, suggesting that this 
is not a result of the dissemination of particular clones but 
rather is due to the spread of multiple specific clones and/
or mobile genetic elements. However, it is interesting that 
these strains presented such resistance to third-generation 
cephalosporins, as these antimicrobial agents are little used 
in Mozambique.
With regard to the resistance phenotype, 100% of the 
isolates were resistant to gentamicin, chloramphenicol, and 
trimethoprim-sulfamethoxazole. The first 2 antibiotics are 
used in the empirical treatment of bacteremia (chloram-
phenicol or penicillin plus gentamicin) whereas ceftriaxone 
is reserved for MDR cases,2 which would not be effective in 
the isolates studied. The transconjugant isolates showed not 
only β-lactam resistance but also the same resistance profile 
to other antibiotic families, which may have an impact on 
the clinical management of the patients in this setting. There 
are 3 main non-exclusive explanations for the finding of 
CTX-M group 1 ESBL resistance genes in these isolates: 
1) the use of third-generation cephalosporins as second-line 
treatment may play a role in the emergence and subsequent 
dissemination of β-lactamase resistance; 2) the resistance 
to β-lactam antibiotics is the result of a co-selection from 
another family of antibiotic resistance mechanisms located 
in the same genetic mobile element; 3) globalization may 
influence the dissemination of ESBLs-carrying isolates in 
the community similar to what has been shown with New 
Dehli metallo-β-lactamase.50 The historical movement of 
the population between Manhiça and neighboring South 
Africa,17 as well as the increasingly more frequent pres-
ence of international travelers to the Manhiça District may 
support the international dissemination of these strains, as 
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Conclusion
As observed in this study, continuously increasing resistance 
among Gram-negative bacteria associated with the emergence 
and spread of MDR isolates, including ESBL producers, is 
an important public health problem with serious implica-
tions in low-income countries. Taking into account that the 
availability of effective antibiotics is a challenge worldwide 
and is of special concern in LMIC due to limited resources, 
clinical microbiology services in Mozambique – and in all 
the Sub-Saharan African countries – need to be reinforced 
in order to perform coordinated antimicrobial resistance 
surveillance and establish national policies to control this 
public health problem.
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